These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 5124188)

  • 1. The role of brain norepinephrine in the anorexic effects of dextroamphetamine and monoamine oxidase inhibitors in the rat.
    Holtzman SG; Jewett RE
    Psychopharmacologia; 1971; 22(2):151-61. PubMed ID: 5124188
    [No Abstract]   [Full Text] [Related]  

  • 2. Differential effects of monoamine oxidase inhibitors.
    Maickel RP; Rompalo AM; Cox RH
    Res Commun Chem Pathol Pharmacol; 1974 Aug; 8(4):727-30. PubMed ID: 4420181
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of lesions and drugs on brain tryptamine.
    Marsden CA; Curzon G
    J Neurochem; 1974 Dec; 23(6):1171-6. PubMed ID: 4281442
    [No Abstract]   [Full Text] [Related]  

  • 4. Serotonin-containing neurons in brain: depression of firing by monoamine oxidase inhibitors.
    Aghajanian GK; Graham AW; Sheard MH
    Science; 1970 Sep; 169(3950):1100-2. PubMed ID: 5449322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of brain dopamine to stress-induced changes in seizure susceptibility.
    Goldberg ME; Salama AI
    Eur J Pharmacol; 1970; 10(3):333-8. PubMed ID: 5422459
    [No Abstract]   [Full Text] [Related]  

  • 6. Histochemical fluorescence detection of changes in central monoamine neurones provoked by drugs acting on the CNS.
    Fuxe K; Hökfelt T
    Triangle; 1971; 10(3):73-84. PubMed ID: 5138525
    [No Abstract]   [Full Text] [Related]  

  • 7. A comparison of the effects of some monoamine oxidase (MAO) inhibitors with 5-hydroxytryptophan (5-HTP) and dihydroxyphenylalanine (DOPA) on spinal synaptic activity.
    Anderson EG; Baker R; Banna N
    Proc West Pharmacol Soc; 1966; 9():40-1. PubMed ID: 5958499
    [No Abstract]   [Full Text] [Related]  

  • 8. Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan.
    Grahame-Smith DG
    J Neurochem; 1971 Jun; 18(6):1053-66. PubMed ID: 4254940
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of five clinically used inhibitors of monoamine oxidase using the fluorescence microscopy method.
    Bartonícek V
    Med Pharmacol Exp Int J Exp Med; 1967; 16(2):142-6. PubMed ID: 5298397
    [No Abstract]   [Full Text] [Related]  

  • 10. Relationship between the pharmacological and biochemical properties of a monoamine oxidase inhibitor preferentially affecting 5-hydroxytryptamine oxidation.
    Christmas AJ; Hall DW; Hayward A; Maxwell DR
    Br J Pharmacol; 1970 May; 39(1):207P-208P. PubMed ID: 5420104
    [No Abstract]   [Full Text] [Related]  

  • 11. Antihypertensive and monoamine oxidase inhibitory activity of 3-amino-2-oxazolidinone (3AO) and its condensation product with 2-substituted-3-formyl-4-oxo-(4H) pyrido(1,2-a)pyrimidines.
    Kaul CL; Grewal RS
    Biochem Pharmacol; 1972 Feb; 21(3):303-16. PubMed ID: 5014489
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of psychoactive drugs on in vivo metabolism of 14C-histamine in mouse brain.
    Schayer RW; Reilly MA
    Arch Int Pharmacodyn Ther; 1973 May; 203(1):123-9. PubMed ID: 4725329
    [No Abstract]   [Full Text] [Related]  

  • 13. The effects of monoamine oxidase inhibitors on spinal synaptic activity.
    Anderson EG; Baker RG; Banna NR
    J Pharmacol Exp Ther; 1967 Dec; 158(3):405-15. PubMed ID: 5299660
    [No Abstract]   [Full Text] [Related]  

  • 14. Monoamine oxidase inhibiting properties of SU-11,739 in the rat. Comparison with pargyline, tranylcypromine and iproniazid.
    Maître L
    J Pharmacol Exp Ther; 1967 Jul; 157(1):81-8. PubMed ID: 6029494
    [No Abstract]   [Full Text] [Related]  

  • 15. Anorexic properties of three monoamine oxidase inhibitors.
    Willis GL; Smith GC
    Pharmacol Biochem Behav; 1982 Dec; 17(6):1135-9. PubMed ID: 7163347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Difference in oral effectiveness of two tyrosine hydroxylase inhibitors.
    Johnson GA; Kim EG; Veldkamp W; Russell R
    Biochem Pharmacol; 1967 Feb; 16(2):401-3. PubMed ID: 6029921
    [No Abstract]   [Full Text] [Related]  

  • 17. An electron microscopic analysis of large granular synaptic vesicles of the brain in relation to monoamine content.
    Bloom FE; Aghajanian GK
    J Pharmacol Exp Ther; 1968 Feb; 159(2):261-73. PubMed ID: 5638647
    [No Abstract]   [Full Text] [Related]  

  • 18. A new and highly sensitive method for measuring 3-methoxytyramine using HPLC with electrochemical detection. Studies with drugs which alter dopamine metabolism in the brain.
    Heal DJ; Frankland AT; Buckett WR
    Neuropharmacology; 1990 Dec; 29(12):1141-50. PubMed ID: 2293058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of monoamine oxidase inhibitors on the N-demethylation and hydrolysis of meperidine.
    Eade NR; Renton KW
    Biochem Pharmacol; 1970 Jul; 19(7):2243-50. PubMed ID: 5520372
    [No Abstract]   [Full Text] [Related]  

  • 20. The role of brain dopamine in the hyperactivity syndrome produced by increased 5-hydroxytryptamine synthesis in rats.
    Green AR; Grahame-Smith DG
    Neuropharmacology; 1974 Nov; 13(10-11):949-59. PubMed ID: 4437730
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.